Results 21 to 30 of about 18,414 (179)
CYP2C9 Genetic Polymorphisms and Warfarin [PDF]
Clinical and Applied Thrombosis/Hemostasis, 2004 The objective of this study was to report 2 cases of CYP2C9 genetic polymorphism and elevated warfarin S: R ratios in patients taking low doses of warfarin, and compare the observed characteristics with those in published reports. Two patients of different age groups and races were evaluated for CYP2C9 genotype and warfarin S: R ratios.
Andrea R, Redman +5 more
openaire +2 more sources
CYP2C9 polymorphisms are associated with phenytoin toxicity in South-Indian epileptic patients
Journal of Dr. NTR University of Health Sciences, 2020 Background and Aims: The contribution of CYP2C9 in phenytoin metabolism is generally modest, but it increases with increasing serum phenytoin concentration.
Rakesh Reddy Reddigari +4 more
doaj +1 more source
Lack of Association of Clinical Factors (SAMe-TTR) with / Genotype and Anticoagulation Control Quality [PDF]
Journal of Stroke, 2015 Background and PurposeAdvantages of new oral anticoagulations may be greater in atrial fibrillation (AF) patients of poor anticoagulation control with warfarin.
Yun Kyung Park +6 more
doaj +1 more source
Acta Biomedica Scientifica, 2022 CYP2C and CYP3A cytochromes are induced by a variety of compounds and affect the pharmacokinetics and pharmacodynamics of a large number of drugs. Currently, the possibility of using copper coordination compounds in antitumor therapy is being actively ...
L. S. Klyushova +3 more
doaj +1 more source
High-Throughput Screening Assays for the Assessment of CYP2C9*1, CYP2C9*2, and CYP2C9*3 Metabolism Using Fluorogenic Vivid® Substrates [PDF]
SLAS Discovery, 2004 CYP2C9 is a genetically polymorphic human cytochrome P450 isozyme involved in the oxidative metabolism of many drugs, including nonsteroidal anti-inflammatory compounds. Individuals genotyped heterozygous or homozygous for CYP2C9 allelic variants have demonstrated altered metabolism of some drugs primarily metabolized by CYP2C9.
Bryan D, Marks +3 more
openaire +2 more sources
Safety of Voriconazole in a Patient with CYP2C9*2/CYP2C9*2 Genotype [PDF]
Antimicrobial Agents and Chemotherapy, 2006 Voriconazole, a broad-spectrum triazole antifungal agent, is well absorbed, with a high oral bioavailability of 96% (6). Maximal plasma concentrations are observed 1 to 2 h after drug administration. The volume of distribution is estimated to be 4.6 liters/kg, and the plasma protein binding is 58%.
Marcus J P, Geist +3 more
openaire +2 more sources
Генотип цитохрому-450 2C9 у хворих на туберкульоз
Medičnì Perspektivi, 2013 The aim of present work was to investigate CYP2С9 polymorphism in the south of Ukraine in TB-patients and comparing with the same data of control group by the example of Odessa region. Gene CYP2С9 polymorphism was studied with the help of PCR (polymerase
V. V. Filyuk +5 more
doaj +1 more source
Frontiers in Systems BiologyLosartan is a selective angiotensin II AT1-receptor antagonist for the treatment of arterial hypertension and heart failure. It is converted to a pharmacologically active metabolite carboxylosartan (E-3174) in the liver mainly by CYP2C9 enzyme, a member ...
Dmitry Babaev +4 more
doaj +1 more source
Frontiers in Endocrinology, 2023 Cytochrome P450 2C9 (CYP2C9) participates in about 15% of clinical drug metabolism, and its polymorphism is associated with individual drug metabolism differences, which may lead to the adverse drug reactions (ADRs).
Qing Zhang +29 more
doaj +1 more source
CYP2C9*2 and CYP2C9*3 Alleles Confer a Lower Risk for Myocardial Infarction [PDF]
Clinical Chemistry, 2004 Cytochrome P-450 (CYP) genes encode for membrane-bound, heme-containing enzymes that catalyze the oxidation of various drugs and endogenous substrates such as vitamin D, steroids, or fatty acids, including arachidonic acid (AA). CYP enzymes of the P-450 2C9 subfamily are produced in the liver, are responsible for 50% of the epoxygenase activity in ...
Marion, Funk +6 more
openaire +2 more sources